The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $624,967 in first-year total cost, median $624,967.
Most frequent study sections
- Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Study Section [AMSC]1
Most frequent institutions
- UNIVERSITY OF ALABAMA AT BIRMINGHAM1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)1UM1AR065705-01 | CURTIS, JEFFREY R.WINTHROP, KEVIN LORING | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $624,967 | AMSC |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.